IPO · 2026-05-19

Pre-IPO Equity Incentive Plans: Dilution Impact on Earnings Per Share

The Hong Kong Stock Exchange (HKEX) recorded 72 new listings on the Main Board in 2024, with aggregate funds raised of approximately HKD 87.5 billion, a 25% increase year-on-year. A detailed review of the 2024 cohort of prospectuses reveals that over 90% of issuers maintained pre-IPO equity incentive plans (EIPs), with an average share pool allocated to employees representing 8.2% of the post-IPO enlarged share capital. For analysts and investors, the accounting treatment of these plans under HKFRS 2 Share-based Payment creates a specific, and often underestimated, drag on earnings per share (EPS). The divergence between the dilutive effect measured by the treasury stock method (TSM) for basic EPS and the full impact under the if-converted method for diluted EPS can be material, particularly for issuers with high-growth vesting schedules. For the 2025-2026 pipeline, where approximately 180 companies are currently in confidential filing with the HKEX, understanding the precise mechanics of this dilution is not an academic exercise; it is a prerequisite for accurate valuation and pricing in the primary and secondary markets.

The Mechanics of Pre-IPO Equity Incentive Plans Under HKFRS 2

Grant Date vs. Vesting Date: The Accounting Trigger

The critical date for recognising share-based payment expense under HKFRS 2 is the grant date, not the vesting date. The grant date is defined as the date at which the entity and the employee reach a mutual understanding of the terms and conditions of the share-based payment arrangement. For a pre-IPO company, the grant date often occurs 12 to 24 months before the listing date. The fair value of the equity instruments granted is measured at this grant date and is recognised as an expense over the requisite service period (the vesting period), with a corresponding credit to equity (share option reserve).

The recognition of this expense directly reduces profit attributable to ordinary equity holders, thereby reducing basic EPS. For a pre-IPO company with a significant share option pool granted two years before listing, the annual charge can represent 3-5% of net profit in the pre-listing period. This expense does not reverse upon listing; it continues to be recognised over the remaining vesting period.

The Treasury Stock Method for Diluted EPS

When calculating diluted EPS in the post-IPO period, HKAS 33 Earnings per Share mandates the use of the treasury stock method (TSM) for share options and other share-based payments. Under TSM, the proceeds from the exercise of options (the exercise price) plus any unrecognised compensation cost (the future service cost) are assumed to be used to repurchase ordinary shares at the average market price during the period.

The formula is: Incremental shares = (Number of options × (Average market price – Exercise price – Unrecognised compensation cost per option)) / Average market price.

For a pre-IPO EIP where the exercise price is set at a nominal value (e.g., HKD 0.01 per share) and the unrecognised compensation cost per option is material (often HKD 5-15 per share for a company listing at HKD 20), the TSM can produce a significant number of incremental shares. For example, if 10 million options with a HKD 0.01 exercise price and HKD 10 unrecognised compensation cost per option are outstanding, and the average market price is HKD 20, the incremental shares under TSM are approximately 5 million shares (10M × (20 – 0.01 – 10) / 20). This directly dilutes diluted EPS.

The If-Converted Method for Convertible Instruments

While most pre-IPO EIPs are straightforward share options, an increasing number of issuers are using convertible preferred shares or convertible bonds as part of employee compensation structures. For these instruments, HKAS 33 requires the if-converted method. This method assumes that the convertible instruments are converted into ordinary shares at the beginning of the period (or at the date of issue, if later). The numerator (profit) is adjusted to add back any interest or dividend expense associated with the convertible instrument, net of tax. The denominator is increased by the number of ordinary shares that would be issued upon conversion.

For a pre-IPO convertible bond with a 5% coupon and a conversion price at 80% of the IPO price, the if-converted method can produce a more aggressive dilutive effect than TSM for options. The adjustment to the numerator (adding back interest) partially offsets the dilution, but the denominator increase is typically larger, resulting in a net reduction in diluted EPS.

The Dilution Impact on EPS: A Case Study Approach

Case Study 1: High-Growth Tech Issuer with Large Option Pool

Consider a hypothetical Hong Kong-listed tech company, “TechCo,” which listed on the Main Board in Q4 2024. Its 2024 annual report (filed under Main Board Rule 13.46(2)(a) within four months of the year-end) is instructive. TechCo had a pre-IPO EIP covering 12% of the post-IPO enlarged share capital. The weighted-average number of options outstanding during 2024 was 45 million. The exercise price was HKD 0.10, and the unrecognised compensation cost at the beginning of the year was HKD 180 million (HKD 4.00 per option). The average market price during 2024 was HKD 25.00.

Under TSM, the incremental shares are calculated as follows:

Proceeds from exercise: 45M × HKD 0.10 = HKD 4.5 million
Unrecognised compensation cost: HKD 180 million
Total assumed proceeds: HKD 184.5 million
Shares repurchased at average market price: HKD 184.5M / HKD 25.00 = 7.38 million
Incremental shares: 45M – 7.38M = 37.62 million

TechCo reported a basic EPS of HKD 1.50 on 300 million weighted-average shares. The diluted EPS, including the 37.62 million incremental shares, was HKD 1.33 (HKD 450 million profit / 337.62 million shares). The dilution was 11.3%. For an IPO prospectus issued in 2025, the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (the Code) paragraph 17.6 requires the sponsor to ensure the profit forecast or estimate, if included, is not misleading. A 11% dilution from a pre-IPO EIP is a material factor that must be clearly disclosed in the “Risk Factors” and “Dilution” sections of the prospectus (HKEX Listing Rules Appendix 1A, paragraph 27(2)).

Case Study 2: Biotech Issuer with Performance-Based Vesting

A pre-revenue biotech issuer, “BioCo,” listed under Chapter 18C of the Main Board Listing Rules (Specialist Technology Companies) in 2025. Its EIP includes performance-based vesting conditions (e.g., achieving a specific clinical trial milestone). Under HKFRS 2, the entity must estimate the number of options expected to vest, adjusting for the probability of achieving the performance condition. This estimation directly impacts the share-based payment expense recognised in the profit or loss and, consequently, basic EPS.

For diluted EPS, HKAS 33 requires that options with performance conditions are only included in the calculation of diluted EPS when the performance condition is met (or is considered to be met) at the reporting date. If the condition is not met, the options are anti-dilutive and are excluded. This creates a binary effect: a successful clinical trial can trigger a sudden, material increase in the denominator for diluted EPS. In BioCo’s case, if 20 million options vested upon FDA approval, the diluted EPS for the quarter of approval would show a step-change dilution of 15-20%, even if the market price did not adjust immediately.

Regulatory and Disclosure Requirements for Pre-IPO EIPs

HKEX Listing Rules: Mandatory Disclosure in the Prospectus

HKEX Main Board Listing Rules Chapter 17 (Share Schemes) sets out the specific disclosure requirements for any share scheme, including pre-IPO EIPs. Rule 17.02 requires that the prospectus must contain full particulars of any share scheme, including:

The total number of shares available for grant under the scheme.
The maximum entitlement of each grantee.
The basis of determining the exercise price.
The vesting period and any performance targets.
The accounting policy for share-based payments (HKFRS 2).

Furthermore, Rule 17.09 requires that the prospectus include a statement of the dilution effect on the shareholding of the existing shareholders. This is typically presented as a table showing the pro-forma diluted EPS and the percentage dilution. The SFC’s Code on Takeovers and Mergers and Share Buy-backs (Takeovers Code) Rule 10 also has implications: if a pre-IPO EIP is structured to grant options to a controlling shareholder or a connected person, it may trigger a mandatory general offer obligation if the exercise of options results in a change of control.

The reporting accountant, appointed under HKEX Listing Rules Rule 4.08, must opine on the pro-forma financial information in the prospectus, including the pro-forma basic and diluted EPS. This opinion is part of the “Accountants’ Report” (Appendix 1A, paragraph 27). The sponsor, under the SFC Code paragraph 17.5, has a duty to ensure that the profit forecast or estimate is prepared with due care and is not misleading. For a pre-IPO EIP, the sponsor must verify that the assumptions used in the TSM and if-converted method calculations are reasonable and consistent with the company’s historical practice and market conditions.

A common oversight in prospectus disclosures is the failure to clearly separate the dilutive effect of the pre-IPO EIP from the dilutive effect of other potential ordinary shares (e.g., warrants, convertible notes). The SFC’s 2024 thematic review of IPO prospectuses (published in January 2025) identified that 15% of reviewed prospectuses did not adequately explain the assumptions behind the TSM calculation, particularly regarding the unrecognised compensation cost per option. This is a specific area where sponsors and reporting accountants are being held to a higher standard in 2025.

Actionable Takeaways for Market Participants

For analysts: When building a DCF or comparable company analysis for a pre-IPO company, explicitly model the share-based payment expense under HKFRS 2 for the forecast period, and apply the treasury stock method to calculate the fully diluted share count for the post-IPO period; a 5-15% dilution drag on EPS is a realistic baseline for companies with an option pool of 8-12% of post-IPO capital.
For company secretaries: Ensure that the board minutes approving the pre-IPO EIP clearly document the grant date, the fair value of the options (with supporting valuation report from an independent valuer), and the vesting schedule, as this documentation is the primary evidence required by the HKEX for compliance with Listing Rules Chapter 17.
For sponsors: In the due diligence work programme, verify that the unrecognised compensation cost per option used in the TSM calculation in the prospectus is consistent with the amortisation schedule derived from the HKFRS 2 valuation model, and that the average market price used is the weighted-average price for the relevant financial period, not a single point estimate.
For IPO investors: Scrutinise the “Dilution” section of the prospectus (typically found in “Summary” or “Risk Factors”) for the pro-forma diluted EPS and the percentage dilution from the pre-IPO EIP; compare this to the industry average (e.g., 8-12% for tech, 5-8% for biotech) to assess whether the company is being overly generous with its option pool.
For management of pre-IPO companies: Consider issuing options with a vesting period that extends at least 12 months post-listing to align the share-based payment expense with the post-IPO financial reporting period, and to reduce the initial dilution shock to EPS in the first annual report after listing.